These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35888774)

  • 21. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
    Sung YK; Lee YH
    J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis.
    Moura RA; Fonseca JE
    Front Med (Lausanne); 2020; 7():607725. PubMed ID: 33614673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
    Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
    Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study.
    Uchida T; Iwamoto N; Fukui S; Morimoto S; Aramaki T; Shomura F; Aratake K; Eguchi K; Ueki Y; Kawakami A
    Rheumatology (Oxford); 2023 Oct; 62(10):3358-3365. PubMed ID: 36794922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
    Hodge JA; Kawabata TT; Krishnaswami S; Clark JD; Telliez JB; Dowty ME; Menon S; Lamba M; Zwillich S
    Clin Exp Rheumatol; 2016; 34(2):318-28. PubMed ID: 26966791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential.
    Cutolo M
    Ther Adv Musculoskelet Dis; 2013 Feb; 5(1):3-11. PubMed ID: 23515130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
    Taylor PC
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
    Scott IC; Hider SL; Scott DL
    Drug Saf; 2018 Jul; 41(7):645-653. PubMed ID: 29500799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
    Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
    BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rheumatoid Arthritis Synovial Fluid Neutrophils Drive Inflammation Through Production of Chemokines, Reactive Oxygen Species, and Neutrophil Extracellular Traps.
    Wright HL; Lyon M; Chapman EA; Moots RJ; Edwards SW
    Front Immunol; 2020; 11():584116. PubMed ID: 33469455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors.
    Rivellese F; Lobasso A; Barbieri L; Liccardo B; de Paulis A; Rossi FW
    Curr Med Chem; 2019; 26(16):2823-2843. PubMed ID: 29424301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
    Shamail GMH; Haridoss M; Natarajan M; Joshua V; Bagepally BS
    Rheumatol Ther; 2022 Apr; 9(2):313-329. PubMed ID: 34902113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: Is there a future?
    Kour G; Choudhary R; Anjum S; Bhagat A; Bajaj BK; Ahmed Z
    Biochem Pharmacol; 2022 Mar; 197():114929. PubMed ID: 35065024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Signal inhibitory receptor on leukocytes-1 regulates the formation of the neutrophil extracellular trap in rheumatoid arthritis.
    Wang L; Yuan J; Cheng Y; Xu Z; Ding M; Li J; Si Y; Zong M; Fan L
    Mol Immunol; 2022 Nov; 151():242-251. PubMed ID: 36182788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutrophils in the Pathogenesis of Rheumatoid Arthritis and Systemic Lupus Erythematosus: Same Foe Different M.O.
    Fresneda Alarcon M; McLaren Z; Wright HL
    Front Immunol; 2021; 12():649693. PubMed ID: 33746988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
    Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
    Front Immunol; 2021; 12():738481. PubMed ID: 34630419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review.
    Emery P; Durez P; Hueber AJ; de la Torre I; Larsson E; Holzkämper T; Tanaka Y
    Arthritis Res Ther; 2021 Jan; 23(1):3. PubMed ID: 33397481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis.
    Tanaka Y; Okumura H; Kim S; Dorey J; Wojciechowski P; Chorąży J; Kato D; Schultz NM
    Rheumatol Ther; 2021 Jun; 8(2):729-750. PubMed ID: 33725321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Rev Clin Immunol; 2019 Jul; 15(7):693-700. PubMed ID: 30987474
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.